International dermatology outcome measures initiative as applied to psoriatic disease outcomes: An update

Joseph F. Merola, April W. Armstrong, Ami Saraiya, John Latella, Amit Garg, Kristina Callis Duffin, Alice B. Gottlieb

Research output: Contribution to journalShort survey

10 Scopus citations

Abstract

Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.

Original languageEnglish (US)
Pages (from-to)959-960
Number of pages2
JournalJournal of Rheumatology
Volume43
Issue number5
DOIs
StatePublished - May 1 2016
Externally publishedYes

Keywords

  • Ideom
  • Omeract
  • Outcome measures
  • Psoriasis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'International dermatology outcome measures initiative as applied to psoriatic disease outcomes: An update'. Together they form a unique fingerprint.

  • Cite this

    Merola, J. F., Armstrong, A. W., Saraiya, A., Latella, J., Garg, A., Duffin, K. C., & Gottlieb, A. B. (2016). International dermatology outcome measures initiative as applied to psoriatic disease outcomes: An update. Journal of Rheumatology, 43(5), 959-960. https://doi.org/10.3899/jrheum.160114